Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses research into JAK inhibitors specifically Ruxolitinib, Pacritinib, and Momelotinib. Ruxolitinb demonstrated positive results in the COMFORT-II trials (NCT00934544), reducing splenomegaly and symptom improvement. Similar results were also seen with pacritinib. There is still no to data on momelotinib from the most recent clinical Phase III trial. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
EHA 2016: Current research into JAK inhibtors- specifially ruxolitinib, pacritinib, and momelotinib
